LXRX
NEUTRAL
$1.71
Live
Lexicon Pharmaceuticals, Inc. · NASDAQ
Target $3.36
(+96.5%)
$0.48
52W Range
$1.84
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$724.49M
P/E
N/A
ROE
-39.7%
Profit margin
-101.1%
Debt/Equity
0.58
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
LXRX exhibits a high-risk, speculative profile with a Piotroski F-Score of 4/9, indicating stable but mediocre financial health. While the company maintains a strong liquidity cushion (Current Ratio 4.88) and has consistently beaten earnings estimates in recent quarters, the fundamental revenue collapse (-79.3% YoY) is a critical red flag. Despite a massive 1-year price surge of 222.6%, the current technical trend is heavily bearish (10/100), suggesting the rally may have peaked. The valuation remains disconnected from current fundamentals, relying entirely on future pipeline success or analyst optimism.
Key Strengths
Strong liquidity position with a Current Ratio of 4.88
High Gross Margin of 86.82% indicating strong product pricing power
Consistent recent earnings beats (3 of last 4 quarters)
Improving Year-over-Year EPS growth (+55.6%)
Manageable leverage with a Debt/Equity ratio of 0.58
Key Risks
Severe revenue contraction (-79.3% YoY and Q/Q)
Deeply negative operating margins (-269.07%)
Strongly bearish technical trend (10/100)
Negative Return on Equity (-39.72%)
High valuation multiples relative to sales (P/S 14.55) amidst shrinking revenue
AI Fair Value Estimate
Based on comprehensive analysis
$2.54
+48.5% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
32
Weak
25
40
35
60
0
AI Verdict
Speculative Recovery
Key drivers: Liquidity runway, EPS improvement, Revenue collapse, Bearish technicals
Confidence
75%
Value
25/100
Trades at a significant premium to book value with no current earnings to support the multiple.
Positives
No standout positives identified.
Watchpoints
- High P/S ratio (14.55)
- High P/B ratio (5.78)
- No Graham Number due to lack of earnings
Future
40/100
Future value is decoupled from current revenue trends, likely dependent on clinical/regulatory catalysts.
Positives
- Positive EPS growth trend
- Analyst target price ($3.36) suggests upside
Watchpoints
- Catastrophic revenue decline
Past
35/100
Long-term value destruction offset by a recent speculative spike.
Positives
- Strong 1-year recovery (+222.6%)
Watchpoints
- Poor 5-year performance (-67%)
- History of volatile earnings surprises
Health
60/100
Strong balance sheet liquidity prevents immediate distress, though operational health is poor.
Positives
- Piotroski F-Score of 4/9 (Stable)
- Excellent Current and Quick ratios
Watchpoints
- Negative ROE and ROA
Dividend
0/100
Typical for biotech; all capital is retained for operations/R&D.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.71
Analyst Target
$3.36
Upside/Downside
+96.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LXRX and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Primary
|
-67.0% | -29.1% | +222.6% | +18.8% | +1.2% | +7.5% |
|
ETON
Eton Pharmaceuticals, Inc.
Peer
|
+251.9% | +598.3% | +130.1% | +26.1% | +58.0% | +4.1% |
|
GYRE
Gyre Therapeutics, Inc.
Peer
|
-40.0% | +134.6% | +1.4% | -7.2% | -11.3% | +3.8% |
|
GDRX
GoodRx Holdings, Inc.
Peer
|
-94.7% | -62.4% | -53.9% | -53.5% | -10.0% | +5.4% |
|
BGM
BGM Group Ltd.
Peer
|
-90.8% | -38.2% | -66.0% | -64.4% | -12.5% | 0.0% |
LXR
Lexicon Pharmaceuticals, Inc.
Primary
5Y
-67.0%
3Y
-29.1%
1Y
+222.6%
6M
+18.8%
1M
+1.2%
1W
+7.5%
ETO
Eton Pharmaceuticals, Inc.
Peer
5Y
+251.9%
3Y
+598.3%
1Y
+130.1%
6M
+26.1%
1M
+58.0%
1W
+4.1%
GYR
Gyre Therapeutics, Inc.
Peer
5Y
-40.0%
3Y
+134.6%
1Y
+1.4%
6M
-7.2%
1M
-11.3%
1W
+3.8%
GDR
GoodRx Holdings, Inc.
Peer
5Y
-94.7%
3Y
-62.4%
1Y
-53.9%
6M
-53.5%
1M
-10.0%
1W
+5.4%
BGM
BGM Group Ltd.
Peer
5Y
-90.8%
3Y
-38.2%
1Y
-66.0%
6M
-64.4%
1M
-12.5%
1W
0.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-8.22
PEG Ratio
N/A
P/B Ratio
5.78
P/S Ratio
14.55
EV/Revenue
13.87
EV/EBITDA
-14.3
Market Cap
$724.49M
Profitability
Profit margins and return metrics
Profit Margin
-101.08%
Operating Margin
-269.07%
Gross Margin
86.82%
ROE
-39.72%
ROA
-12.65%
Growth
Revenue and earnings growth rates
Revenue Growth
-79.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-79.31%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.58
Moderate
Current Ratio
4.88
Strong
Quick Ratio
4.73
Excellent
Cash/Share
$0.23
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
96.3%
Op. Margin
-269.1%
Net Margin
-282.7%
Total Assets
$0.2B
Liabilities
$0.1B
Equity
$0.1B
Debt/Equity
0.72x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-03-05
$-0.04
+43.6% surprise
2025-11-06
$-0.04
+39.4% surprise
2025-08-06
$0.01
+112.9% surprise
Healthcare Sector Comparison
Comparing LXRX against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-39.72%
This Stock
vs
-86.0%
Sector Avg
-53.8%
(Below Avg)
Profit Margin
-101.08%
This Stock
vs
-11.76%
Sector Avg
+759.6%
(Superior)
Debt to Equity
0.58
This Stock
vs
3.51
Sector Avg
-83.5%
(Less Debt)
Revenue Growth
-79.3%
This Stock
vs
90.15%
Sector Avg
-188.0%
(Slower)
Current Ratio
4.88
This Stock
vs
3.67
Sector Avg
+33.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LXRX
Lexicon Pharmaceuticals, Inc.
|
NEUTRAL | $724.49M | - | -39.7% | -101.1% | $1.71 | |
|
ETON
Eton Pharmaceuticals, Inc.
|
BEARISH | $720.17M | - | -18.2% | -5.8% | $26.39 | Compare |
|
GYRE
Gyre Therapeutics, Inc.
|
BEARISH | $711.9M | 369.5 | 8.2% | 4.3% | $7.39 | Compare |
|
GDRX
GoodRx Holdings, Inc.
|
BEARISH | $739.96M | 24.0 | 4.5% | 3.8% | $2.16 | Compare |
|
BGM
BGM Group Ltd.
|
BEARISH | $746.32M | - | -16.5% | -26.3% | $3.72 | Compare |
LXRX
Lexicon...
NEUTRAL
Mkt Cap
$724M
P/E
-
ROE
-39.7%
Price
$1.71
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | COIANTE SCOTT M | Chief Financial Officer | Stock Award | 160,237 | - |
| 2026-02-27 | CRUM BRIAN T | General Counsel | Stock Award | 273,006 | - |
| 2026-02-27 | DEFRANCESCO LISA | Officer | Stock Award | 152,864 | - |
| 2026-02-27 | GRANOWITZ CRAIG B. M.D., PH.D. | Officer | Stock Award | 312,276 | - |
| 2026-02-27 | MCDERMOTT WENDY | Officer | Stock Award | 224,406 | - |
| 2026-02-27 | EXTON MICHAEL | Chief Executive Officer | Stock Award | 503,263 | - |
| 2026-02-27 | MARTENS RACHEL YAP | Officer | Stock Award | 67,090 | - |
| 2026-02-27 | GOPINATHAN SUMA | Officer | Stock Award | 99,950 | - |
| 2026-02-25 | DEBBANE RAYMOND | Director | Purchase | 2,000 | $2,980 |
| 2026-02-23 | DEBBANE RAYMOND | Director | Purchase | 100,000 | $147,000 |
| 2026-02-20 | DEBBANE RAYMOND | Director | Purchase | 150,000 | $219,755 |
| 2026-02-18 | DEBBANE RAYMOND | Director | Purchase | 268,497 | $352,889 |
| 2026-02-02 | INVUS GLOBAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 22,400,000 | $29,120,000 |
| 2026-02-02 | INVUS GLOBAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,538,462 | $2,000,001 |
COIANTE SCOTT M
Chief Financial Officer
2026-02-27
160,237 shares
CRUM BRIAN T
General Counsel
2026-02-27
273,006 shares
DEFRANCESCO LISA
Officer
2026-02-27
152,864 shares
GRANOWITZ CRAIG B. M.D., PH.D.
Officer
2026-02-27
312,276 shares
MCDERMOTT WENDY
Officer
2026-02-27
224,406 shares
EXTON MICHAEL
Chief Executive Officer
2026-02-27
503,263 shares
MARTENS RACHEL YAP
Officer
2026-02-27
67,090 shares
GOPINATHAN SUMA
Officer
2026-02-27
99,950 shares
DEBBANE RAYMOND
Director
2026-02-25
2,000 shares
·
$2,980
DEBBANE RAYMOND
Director
2026-02-23
100,000 shares
·
$147,000
DEBBANE RAYMOND
Director
2026-02-20
150,000 shares
·
$219,755
DEBBANE RAYMOND
Director
2026-02-18
268,497 shares
·
$352,889
INVUS GLOBAL MANAGEMENT, LLC
Beneficial Owner of more than 10% of a Class of Security
2026-02-02
22,400,000 shares
·
$29,120,000
INVUS GLOBAL MANAGEMENT, LLC
Beneficial Owner of more than 10% of a Class of Security
2026-02-02
1,538,462 shares
·
$2,000,001
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
5 analysts
HC Wainwright & Co.
2026-03-23
Buy
Buy
Citigroup
2026-03-10
Buy
Buy
HC Wainwright & Co.
2026-03-05
Buy
Buy
Past News Coverage
Recent headlines mentioning LXRX from our newsroom.
Newest → oldest
No matching news yet.